COMMUNIQUÉS West-GlobeNewswire

NeurAxis Positions for Next Phase of Commercial Growth with Appointment of Craig Blanchard as Chief Commercial Officer
29/09/2026
CARMEL, Ind., Sept. 29, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating [...]
ABBYY Appoints Paula Sanders to Chief Customer Experience Officer, Providing Customers a Single, End-to-End Experience
29/09/2026
AUSTIN, Texas, Sept. 29, 2026 (GLOBE NEWSWIRE) -- ABBYY today announced the appointment of Paula Sanders to Chief Customer Experience Officer (CCXO) to provide customers a consistent, connected experience across every [...]
Why Weight Loss Plateaus Happen: 5 Metabolic Causes
29/09/2026
Trilivy™ is designed to address the challenges of metabolic dysfunction Clients on Trilivy's Reset 5 & 1 Plan who work with a coach lose up to 10 times more weight and 17 times more fat compared to self-directed [...]
Aclarion Welcomes NYU Langone Health to CLARITY Trial Network, Now Enrolling at Eleven Sites
29/09/2026
NYU Langone Health is a nationally recognized academic medical center with deep expertise in spine surgery, minimally invasive procedures, robotic spine surgery, and clinical research CLARITY is a prospective, [...]
CDT Highlights Sarborg’s Expanding Quantum Computing IP Portfolio and Application to Drug Discovery
29/09/2026
NAPLES, Fla. and CAMBRIDGE, United Kingdom, Sept. 29, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“ CDT ” or the “ Company ”) today notes the announcement from Sarborg Limited regarding the filing of new [...]
OKYO Pharma Presents and Participates at Upcoming Ophthalmic Scientific Conferences
29/09/2026
OKYO demonstrates continued commitment to optometry and ophthalmology LONDON and NEW YORK, Sept. 29, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO ), a clinical-stage biopharmaceutical company developing [...]
BeyondSpring Announces FDA Fast Track Designation for Plinabulin in Post-ICI Non-Squamous NSCLC and Strategic Transaction to Advance Global Phase 3 DUBLIN-4 Trial Toward Planned Interim Analysis
29/09/2026
FDA Fast Track designation represents an important regulatory milestone for the Plinabulin and docetaxel combination as an anticancer regimen in 2L/3L advanced or metastatic non-squamous NSCLC without actionable genomic [...]
Invivyd Announces Positive Topline Results from LIBERTY Phase 3 Study Demonstrating VYD2311 Safety and Tolerability Superior to mRNA-based COVID-19 Vaccine; Announces Regulatory Submission Plans for VYD2311
29/09/2026
VYD2311 met all primary and secondary endpoints comparing VYD2311 to an mRNA-based COVID-19 vaccine, demonstrating VYD2311 safety and tolerability that is clinically and statistically superior to the safety and [...]
PolarityBio’s Phase 3 COVER DFUS II Trial Selected for First-to-Podium Presentation at SAWC Fall 2026
29/09/2026
Pivotal SkinTE® data in non-healing Wagner Grade 1 diabetic foot ulcers to be presented by Study Chair Robert S. Kirsner, MD, PhD, on October 16 SALT LAKE CITY, Sept. 29, 2026 (GLOBE NEWSWIRE) -- PolarityBio® , a late- [...]
Ocugen to Participate in Upcoming October Investor and Industry Conferences
29/09/2026
MALVERN, Pa., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology company developing gene therapies for blindness diseases, today announced that members of [...]
Boehringer Ingelheim investments into sustainability-related programs and health partnerships to reach EUR 500 million
29/09/2026
Company investments from the past five years, together with the forecast for 2026, are projected to reach EUR 500 million by year-end 2026, encompassing all expenditure on sustainability-related projects and health [...]
Immix Biopharma Announces Pricing of $125 Million Underwritten Offering of Common Stock
29/09/2026
LOS ANGELES, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “we” or “us” or “IMMX”), a global leader in relapsed/refractory AL Amyloidosis, today announced the pricing of an [...]
Kraig Biocraft Laboratories Ships its First Commercial Spider Silk Yarn Order for Performance Sports Brand
29/09/2026
Milestone Marks Recombinant Spider Silk’s Move from Scaled Production to a First-of-Its-Kind Performance Textile ANN ARBOR, Mich., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“the [...]
uniQure Announces Additional Data from Ongoing Phase I/II Studies of ifezuntirgene inilparvovec (AMT-130) in Huntington’s Disease Showing Continued Slowing of Disease Progression
29/09/2026
~ In 12 high-dose patients at 48 months, both cUHDRS and TFC continued to demonstrate meaningful slowing of disease progression and clear dose-dependent response; the primary endpoint of cUHDRS showed 44% slowing of [...]
Cellectar Biosciences to Present Compelling Efficacy Data from Phase 2 CLOVER WaM Subset Analysis of Iopofosine I 131 in Patients Refractory/Resistant to BTK Inhibitor Therapy at International Workshop for Waldenström Macroglobulinemia
29/09/2026
Demonstrated Major Response Rate of 79.2%, Overall Response Rate of 87.5%, and Duration of Response Exceeding 16 Months in Subset Analysis of Patients Treated with Iopofosine I 131 Immediately Post-BTKi Therapy Data [...]
Medicus Pharma Submits Optimized Teverelix® Registrational Protocol to FDA to Create Partner Ready Program in Advanced Prostate Cancer
29/09/2026
Proposed seamless design would incorporate previously FDA-cleared dose-optimization work into a single registration-intent program aligning it with Company’s capital-efficient development strategy PHILADELPHIA, Sept. 29 [...]
Optimi Health Appoints Melanie Pump to Board of Directors
29/09/2026
Seasoned finance executive brings more than 25 years of leadership experience across technology, digital infrastructure, software, fintech and emerging growth companies VANCOUVER, British Columbia, Sept. 29, 2026 (GLOBE [...]
Cartesian Therapeutics Announces Additional Retreatment Data for Descartes-08 Highlighting Deep and Durable Responses in Patients with Myasthenia Gravis
29/09/2026
Descartes–08 demonstrated improvement in mean change from baseline in MG-ADL following initial treatment and retreatment; mean MG-ADL reduction of 6.6 points at Month 12 following retreatment Median interval between end [...]
Cognition Therapeutics Schedules a Type C Meeting with FDA to Align on Endpoints for Phase 3 Trial of Zervimesine (CT1812) in DLB
29/09/2026
October 20th Meeting with the Division of Neurology Expected to Define Endpoint for Phase 3 PURCHASE, N.Y., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. , (the Company or Cognition) (NASDAQ: CGTX), a [...]

Pages